News
How do you solve the Kyrsten Sinema problem?
Bisexual senator absent from WH Pride reception
Attendees of the White House reception for Pride month last week included high-profile LGBTQ leaders from activist groups, state legislatures, and the federal government. One lawmaker, however, was conspicuously absent.
Sen. Kyrsten Sinema (D-Ariz.), the only out bisexual in Congress, didn’t attend the event — an absence that stood out as members of the House LGBTQ Congressional Equality Caucus were there. Sen. Tammy Baldwin (D-Wis.), Sinema’s LGBTQ companion in the Senate, also showed up and was in the front row for President Biden’s remarks.
When the Washington Blade reached out to Sinema’s office to ask why the senator skipped the reception, her staff confirmed she had been invited.
“Kyrsten was invited, but was unable to attend as the Senate had recessed Thursday evening for state work period,” said Hannah Hurley, a Sinema spokesperson.
But the Senate recess didn’t stop Baldwin from attending the Pride reception.
It’s not the only event Sinema has skipped in recent weeks. When Vice President Kamala Harris hosted a dinner at the White House for all women members of the Senate, Sinema was the only Democrat not in attendance.
The absence of Sinema is almost metaphorical as she has become the target of ire for progressives who view her as an obstructionist to their agenda in the Senate.
Sinema, as she articulated in a recent op-ed for the Washington Post, has come out in strong defense of the filibuster in the Senate, which has been criticized as a relic of structuralism racism (although she’s not the only Senate Democrat to oppose dropping the filibuster).
“It’s no secret that I oppose eliminating the Senate’s 60-vote threshold,” Sinema writes. “I held the same view during three terms in the U.S. House, and said the same after I was elected to the Senate in 2018. If anyone expected me to reverse my position because my party now controls the Senate, they should know that my approach to legislating in Congress is the same whether in the minority or majority.”
As a result of her position, Sinema has been accused of holding up key legislation like the Equality Act, which would expand LGBTQ protections under the law. (It should be noted the bill as it stands doesn’t have unanimous support in the Democratic caucus and wouldn’t even pass without the filibuster on a majority vote.)
Also, the dramatic thumbs down she gave on the Senate floor on an amendment to raise the minimum wage to $15 an hour was interpreted as an insult to progressives pushing for the increase.
The transition for Sinema is remarkable. Starting her political career for the Arizona Legislature as a Green Party candidate who once dressed up in a tutu to oppose the Iraq war, Sinema’s latest incarnation as a conservative Democrat has some of her one-time supporters scratching their heads.
That will make things complicated for LGBTQ advocacy groups like the Human Rights Campaign and the LGBTQ Victory Fund, which have endorsed her efforts to win election, and for Democrats who sold her as the only out bisexual in Congress.
Sinema, after winning election in 2018 to a six-year term, will be in the Senate for a while and won’t face re-election until 2024. But progressives are already clamoring for LGBTQ advocacy groups to take a hard line with her regarding any future support.
Michelangelo Signorile, a progressive activist and Sinema critic, went so far in an email to the Blade as to say LGBTQ groups should withhold their endorsements entirely from Sinema.
“LGBTQ groups definitely shouldn’t be endorsing anyone blocking the Equality Act from being passed. Right now that includes every Republican and Joe Manchin and Kyrsten Sinema, who refuse to eliminate the filibuster,” Signorile said. “So of course they shouldn’t endorse her. How could the Human Rights Campaign or Victory Fund have any credibility while telling the community to invest hard-earned dollars with this politician?”
Sinema has always taken a one-foot-in, one-foot-out approach to her sexual orientation as a political figure. Accepting endorsements from LGBTQ groups, Sinema has attended events after her election hosted by them, such as an event with new LGBTQ members of Congress upon her election to the U.S. House in 2012. But Sinema has dodged questions about her bisexuality, telling the Washington Post in 2013 she doesn’t understand “why it’s big deal.”
The LGBTQ Victory Fund, for its part, is putting a degree of distance between itself and Sinema in response to inquires from the Blade, but not repudiating its support for her entirely.
Elliot Imse, a Victory Fund spokesperson, said his organization endorsed Sinema when the choice for Arizona voters was between her and “the anti-LGBTQ Republican candidate Martha McSally.”
“She is not currently endorsed by Victory Fund and we won’t be considering 2024 endorsements until summer 2023 – and much will happen between now and then,” Imse said. “As with all our incumbent candidates, the Victory Campaign Board will review her efforts to advance equality while in office as it is a key criteria for our endorsement.”
In response to an inquiry on whether the Victory Fund has reached out to Sinema about her policy positions, Imse said that would be inconsistent with his organization’s mission.
“Victory Fund has a very clear mission and we believe organizations are most successful when they remain laser-focused on that mission – so we do not take positions on specific policy or procedural questions,” Imse said. “We endorse and support LGBTQ candidates who will fight for and advance equality legislation and policies once in office and the LGBTQ members of Congress we’ve helped elect are the most outspoken and passionate voices on the Equality Act and other LGBTQ rights legislation.”
Having that “laser-focus,” however, isn’t true for other LGBTQ political groups, which do both endorsements and lobbying before Congress. Chief among them is the nation’s largest LGBTQ group, the Human Rights Campaign.
The Human Rights Campaign, however, didn’t respond to multiple requests for comment on Sinema or any discussions the organization has with her. That silence, however, likely won’t be enough for progressive activists angered with Sinema.
Signorile said Sinema’s absence from the White House should be seen as a red flag for LGBTQ advocacy groups on any future support.
“Sinema, by not attending Pride at the WH, doesn’t even make herself visible there. It’s almost like she wants to distance herself from being part of the community,” Signorile said. “She never talks about being bisexual, doesn’t discuss her coming out story — even if you ask her — and I defy anyone to find me a recent time in which she’s discussed being part of this community.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Rehoboth Beach
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
$4.5 million listing includes real estate; business sold separately
Gay gasps could be heard around the DMV earlier this week when a real estate listing for Rehoboth Beach’s iconic Blue Moon bar and restaurant hit social media.
Take a breath. The Moon is for sale but the longtime owners are not in a hurry and are committed to preserving its legacy as a gay-friendly space.
“We had no idea the interest this would create,” Tim Ragan, one of the owners, told the Blade this week. “I guess I was a little naive about that.”
Ragan explained that he and longtime partner Randy Haney are separating the real estate from the business. The two buildings associated with the sale are listed by Carrie Lingo at 35 Baltimore Ave., and include an apartment, the front restaurant (6,600 square feet with three floors and a basement), and a secondary building (roughly 1,800 square feet on two floors). They are listed for $4.5 million.
The bar and restaurant business is being sold separately; the price has not been publicly disclosed.
But Ragan, who has owned the Moon for 20 years, told the Blade nothing is imminent and that the Moon remains open through the holidays and is scheduled to reopen for the 2026 season on Feb. 10. He has already scheduled some 2026 entertainment.
“It’s time to look for the next people who can continue the history of the Moon and cultivate the next chapter,” Ragan said, noting that he turns 70 next year. “We’re not panicked; we separated the building from the business. Some buyers can’t afford both.”
He said there have been many inquiries and they’ve considered some offers but nothing is firm yet.
Given the Moon’s pioneering role in queering Rehoboth Beach since its debut 44 years ago in 1981, many LGBTQ visitors and residents are concerned about losing such an iconic queer space to redevelopment or chain ownership.
“That’s the No. 1 consideration,” Ragan said, “preserving a commitment to the gay community and honoring its history. The legacy needs to continue.” He added that they are not inclined to sell to one of the local restaurant chains.
You can view the real estate listing here.
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
